CEBPB and neoplasm: In the tumor-bearing murine heart transplantation model, ICT potentiated the immunosuppressive efficacy of tacrolimus while reducing the tumor burden.<h4>Conclusions</h4>While exerting antitumor effects, ICT attenuates allograft rejection by targeting the CEBPB/PIM1 axis, thereby suppressing CD4<sup>+</sup> T-cell activation, proliferation, and Th1 differentiation.